A Nonpeptide Antagonist Reveals a Highly Glycosylated State of the Rabbit Kinin B1 Receptor
Open Access
- 1 April 2006
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 69 (4) , 1146-1157
- https://doi.org/10.1124/mol.105.019976
Abstract
The inducible kinin B1 receptor is emerging as an attractive therapeutic target for the treatment of pain and inflammation. Although many studies described its regulation at the transcriptional level, little is known about the maturation of the B1 receptor. Using two human embryonic kidney (HEK) 293 cell lines stably expressing rabbit B1 receptors tagged with the yellow fluorescent protein at the C terminus (B1R-YFP) or the N-terminal myc epitope (myc-B1R), we showed that receptors are mainly retained in a perinuclear compartment and detectable as low-glycosylated species under control conditions. Interference with the ubiquitin-proteasome pathway function (proteasome inhibitors, coexpression with dominant-negative ubiquitin) blocked B1 receptor degradation and amplified its intracellular accumulation. A potent nonpeptide antagonist specifically increased the abundance of highly glycosylated B1R-YFP forms at the cell surface (accessible to chymotrypsin digestion in intact cells); this compound augmented low-glycosylated receptors in brefeldin A-treated cells, supporting the hypothesis that it reaches a newly synthesized receptor in the endoplasmic reticulum. Cell-impermeant peptide or low-affinity nonpeptide B1 receptor antagonists failed to influence the level of highly glycosylated receptors. Chemical chaperones stabilized all B1R-YFP species and up-regulated endogenous B1 receptors expressed at the surface of rabbit smooth muscle cells. Although myc-B1Rs behaved similarly to B1R-YFP in most aspects, antibody-based detection assays failed to reveal highly glycosylated species of this construct. Taken together, these results show that B1 receptors overexpressed in HEK 293 cells are degraded by the proteasome. Furthermore, a pharmacological chaperone highlights the existence of a highly N-glycosylated form of the rabbit kinin B1 receptor at the cell surface.Keywords
This publication has 38 references indexed in Scilit:
- Discovery of a Dual-Function Peptide That Combines Aminopeptidase N Inhibition and Kinin B1 Receptor AntagonismThe Journal of Pharmacology and Experimental Therapeutics, 2006
- ENDOPLASMIC RETICULUM–ASSOCIATED DEGRADATIONAnnual Review of Cell and Developmental Biology, 2005
- Endogenous Aminopeptidase N Decreases the Potency of Peptide Agonists and Antagonists of the Kinin B1 Receptors in the Rabbit AortaThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Inefficient Maturation of the Rat Luteinizing Hormone ReceptorJournal of Biological Chemistry, 2005
- Potent and Orally Bioavailable Non-Peptide Antagonists at the Human Bradykinin B1 Receptor Based on a 2-Alkylamino-5-sulfamoylbenzamide CoreJournal of Medicinal Chemistry, 2004
- The Human B1 Bradykinin Receptor Exhibits High Ligand-independent, Constitutive ActivityJournal of Biological Chemistry, 2001
- Newly Synthesized Human δ Opioid Receptors Retained in the Endoplasmic Reticulum Are Retrotranslocated to the Cytosol, Deglycosylated, Ubiquitinated, and Degraded by the ProteasomeJournal of Biological Chemistry, 2001
- Antagonist-Induced Intracellular Sequestration of Rabbit Bradykinin B 2 ReceptorHypertension, 2000
- The Role of Multiubiquitination in Dislocation and Degradation of the α Subunit of the T Cell Antigen ReceptorJournal of Biological Chemistry, 1999
- Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from Golgi to ERCell, 1989